R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Bibliographic Details
Main Authors:	Diana Al-Sarayfi, Frederik O. Meeuwes, Müjde Durmaz, Djamila E. Issa, Rolf E. Brouwer, Aart Beeker, Anna van Rhenen, Pim G. N. J. Mutsaers, Lara H. Böhmer, Marjolein W. M. van der Poel, Liane te Boome, Tom van Meerten, Martine E. D. Chamuleau, Josée M. Zijlstra, Mirian Brink, Marcel Nijland
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-09-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00723-4

Similar Items

P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP
by: Diana Al-Sarayfi, et al.
Published: (2023-08-01)

LINFOMA T INTESTINAL MONOMÓRFICO EPITELIOTRÓPICO NUMA IDOSA TRATADO COM O ESQUEMA CEOP (SEM VINCRISTINA)
by: FA Silva, et al.
Published: (2021-10-01)

P1139: COMPARISON OF 6XR-CHOP21 VERSUS 6XR-CHOP+2R FOR ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A PROPENSITY SCORE WEIGHTED POPULATION-BASED ANALYSIS
by: Carolien Maas, et al.
Published: (2023-08-01)

Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane
by: Marijke Linschoten, et al.
Published: (2025-01-01)

Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
by: Carolien C. H. M. Maas, et al.
Published: (2024-09-01)

P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY
by: Elise R.A. Pennings, et al.
Published: (2023-08-01)

The role of iron in anthracycline cardiotoxicity
by: Elena eGammella, et al.
Published: (2014-02-01)

Anthracyclines
by: Alison Cheong, et al.
Published: (2018-12-01)

P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
by: A. M. Spanjaart, et al.
Published: (2022-06-01)

Removal of ineligible outcome cases reduces confounding
by: Walker AM, et al.
Published: (2018-05-01)

Anthracycline cardiomyopathy
by: Vasiliy Nefedovich Anokhin, et al.
Published: (2011-10-01)

Cardiotoxicity of Anthracyclines
by: Daniela Cardinale, et al.
Published: (2020-03-01)

Anthracycline Cardiotoxicity
by: Umberto Campia, MD, MSc, et al.
Published: (2020-06-01)

P1209: INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS
by: F. O. Meeuwes, et al.
Published: (2022-06-01)

Anthracycline-induced cardiotoxicity and senescence
by: Laura K. Booth, et al.
Published: (2022-11-01)

P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS
by: V. de Jonge, et al.
Published: (2022-06-01)

Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
by: Elise R. A. Pennings, et al.
Published: (2024-01-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
by: Carmelo Gurnari, et al.
Published: (2022-12-01)

How I manage frontline transplant-ineligible multiple myeloma
by: Daniele Derudas, et al.
Published: (2020-09-01)

Percutaneous Radiofrequency Ablation of Thyroid Carcinomas Ineligible for Surgery, in the Elderly
by: Pierre Yves Marcy, et al.
Published: (2023-08-01)

Office-Based Laryngeal Biopsy in Patients Ineligible for General Anesthesia
by: Francesco Mozzanica, et al.
Published: (2020-11-01)

Notification Strategy and Predictors of Outcome in Stroke Ineligible for Reperfusion Therapies
by: Ágnes Mirolovics, et al.
Published: (2019-10-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

When to reinvite initially ineligible populations for targeted lung cancer screening?
by: Matthew Sperrin, et al.
Published: (2024-06-01)

Genetics of Anthracycline-Associated Cardiotoxicity
by: Talal Khalid Al-Otaibi, et al.
Published: (2022-04-01)

Anthracycline-Induced Vascular Dysfunction
by: Douglas B. Sawyer, MD, PhD
Published: (2020-09-01)

Management and outcome of anthracycline cardiomyopathy
by: A.A. Dhir, et al.
Published: (2014-11-01)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
by: J. Doorduijn, et al.
Published: (2022-06-01)

Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
by: Devon Miller, et al.
Published: (2022-09-01)

Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015
by: Avinash G. Dinmohamed, et al.
Published: (2017-09-01)

Metabolic engineering of Streptomyces peucetius for biosynthesis of N,N-dimethylated anthracyclines
by: Mandy B. Hulst, et al.
Published: (2024-02-01)

Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse.
by: Stefano Toldo, et al.
Published: (2013-01-01)

CHANGE OF THE LEFT VENTRICLE FUNCTIONING IN LYMPHOMA TREATED WITH ANTHRACYCLINE ANTIBIOTICS
by: K. V. Shuykova, et al.
Published: (2016-01-01)

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T-cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma
by: A. Vera de Jonge, et al.
Published: (2024-07-01)

Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines
by: Vivian I. Franco, et al.
Published: (2011-01-01)